Nidhi Jyotsana

Dr. Nidhi Jyotsana

Vanderbilt University
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2013 in Blood
Verified
Journal Article
Closed access
PDF file
ACAnuhar Chaturvedi
Anuhar Chaturvedi
MCMichelle Maria Araujo Cruz
Michelle Maria Araujo Cruz
NJNidhi Jyotsana
Nidhi Jyotsana
ASAmit Sharma
Amit Sharma
HYHaiyang Yun
Haiyang Yun
MHMichael Heuser
Michael Heuser
Mutations in the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are frequently found in glioma, acute myeloid leukemia (AML), melanoma, thyroid cancer, and chondrosarcoma patients. Mutant IDH produces 2-hydroxyglutarate (2HG), which induces histone- and DNA-hypermethylation through inhibition of epigenetic regulators. We investigated the role of mutant IDH1 using the mouse transplantation assay. Mutant IDH1 alone did not transform hematopoietic cells during 5 months of observation. However, mutant IDH1 greatly accelerated onset of myeloproliferative disease–like myeloid leukemia in mice in cooperation with HoxA9 with a mean latency of 83 days compared with cells expressing HoxA9 and wild-type IDH1 or a control vector (167 and 210 days, respectively, P = .001). Mutant IDH1 accelerated cell-cycle transition through repression of cyclin-dependent kinase inhibitors Cdkn2a and Cdkn2b, and activated mitogen-activated protein kinase signaling. By computational screening, we identified an inhibitor of mutant IDH1, which inhibited mutant IDH1 cells and lowered 2HG levels in vitro, and efficiently blocked colony formation of AML cells from IDH1-mutated patients but not of normal CD34+ bone marrow cells. These data demonstrate that mutant IDH1 has oncogenic activity in vivo and suggest that it is a promising therapeutic target in human AML cells. Key Points IDH1 promotes leukemogenesis in vivo in cooperation with HoxA9. Pharmacologic inhibition of mutant IDH1 efficiently inhibits AML cells of IDH1-mutated patients but not of normal CD34+ bone marrow cells.

18 May 2019 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
NJNidhi Jyotsana
Nidhi Jyotsana
ASAmit Sharma
Amit Sharma
ACAnuhar Chaturvedi
Anuhar Chaturvedi
RBRamachandramouli Budida
Ramachandramouli Budida
MSMichaela Scherr
Michaela Scherr
MHMichael Heuser
Michael Heuser

5 July 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
NJNidhi Jyotsana
Nidhi Jyotsana
ZZZhenjiang Zhang
Zhenjiang Zhang
LHLauren E. Himmel
Lauren E. Himmel
FYFang Yu
Fang Yu
MKMichael King
Michael King
Minimal delivery of E-selectin–TRAIL liposomes can effectively target postsurgical metastasis in triple-negative breast cancer.

11 April 2016 in Leukemia
Verified
Journal Article
Open access
PDF file
ACA Chaturvedi
A Chaturvedi
MCM M Araujo Cruz
M M Araujo Cruz
NJNidhi Jyotsana
Nidhi Jyotsana
ASA Sharma
A Sharma
RGR Goparaju
R Goparaju
MHMichael Heuser
Michael Heuser
Canonical mutations in IDH1 and IDH2 produce high levels of the R-enantiomer of 2-hydroxyglutarate (R-2HG), which is a competitive inhibitor of α-ketoglutarate (αKG)-dependent enzymes and a putative oncometabolite. Mutant IDH1 collaborates with HoxA9 to induce monocytic leukemia in vivo. We used two mouse models and a patient-derived acute myeloid leukemia xenotransplantation (PDX) model to evaluate the in vivo transforming potential of R-2HG, S-2HG and αKG independent of the mutant IDH1 protein. We show that R-2HG, but not S-2HG or αKG, is an oncometabolite in vivo that does not require the mutant IDH1 protein to induce hyperleukocytosis and to accelerate the onset of murine and human leukemia. Thus, circulating R-2HG acts in a paracrine manner and can drive the expansion of many different leukemic and preleukemic clones that may express wild-type IDH1, and therefore can be a driver of clonal evolution and diversity. In addition, we show that the mutant IDH1 protein is a stronger oncogene than R-2HG alone when comparable intracellular R-2HG levels are achieved. We therefore propose R-2HG-independent oncogenic functions of mutant IDH1 that may need to be targeted in addition to R-2HG production to exploit the full therapeutic potential of IDH1 inhibition.

29 June 2020 in Cellular and Molecular Bioengineering
Verified
Journal Article
Closed access
PDF file
NJNidhi Jyotsana
Nidhi Jyotsana
MKMichael R. King
Michael R. King

26 September 2020 in Cancers
Verified
Journal Article
Open access
PDF file
SMSagarajit Mohanty
Sagarajit Mohanty
NJNidhi Jyotsana
Nidhi Jyotsana
ASAmit Sharma
Amit Sharma
AKArnold Kloos
Arnold Kloos
RGRazif Gabdoulline
Razif Gabdoulline
MHMichael Heuser
Michael Heuser
NUP98-NSD1-positive acute myeloid leukemia (AML) is a poor prognostic subgroup that is frequently diagnosed in pediatric cytogenetically normal AML. NUP98-NSD1-positive AML often carries additional mutations in genes including FLT3, NRAS, WT1, and MYC. The purpose of our study was to characterize the cooperative potential of the fusion and its associated Neuroblastoma rat sarcoma (NRAS) mutation. By constitutively expressing NUP98-NSD1 and NRASG12D in a syngeneic mouse model and using a patient-derived xenograft (PDX) model from a NUP98-NSD1-positive AML patient, we evaluated the functional role of these genes and tested a novel siRNA formulation that inhibits the oncogenic driver NUP98-NSD1. NUP98-NSD1 transformed murine bone marrow (BM) cells in vitro and induced AML in vivo. While NRASG12D expression was insufficient to transform cells alone, co-expression of NUP98-NSD1 and NRASG12D enhanced the leukemogenicity of NUP98-NSD1. We developed a NUP98-NSD1-targeting siRNA/lipid nanoparticle formulation that significantly prolonged the survival of the PDX mice. Our study demonstrates that mutated NRAS cooperates with NUP98-NSD1 and shows that direct targeting of the fusion can be exploited as a novel treatment strategy in NUP98-NSD1-positive AML patients.